Menu

Recent Interviews

Jerre Foo, Corporate Development Executive, Silkroad Nickel

Jerre Foo
Corporate Development Executive | Silkroad Nickel
50 Armenian Street #03-04, 179938 Singapore (SGP)

enquiries@silkroadnickel.com

+65 6327 8971

Silkroad Nickel: 'The course is set for dynamic profit growth.'


Dr. Thomas Gutschlag, CEO, Deutsche Rohstoff AG

Dr. Thomas Gutschlag
CEO | Deutsche Rohstoff AG
Q7, 24, 68161 Mannheim (D)

info@rohstoff.de

+49 621 490 817 0

Interview Deutsche Rohstoff AG: "We can imagine additional investments in the field of electromobility."


Steve Cope, President, CEO and Director, Silver Viper

Steve Cope
President, CEO and Director | Silver Viper
1055 W Hastings St Suite 1130, V6E 2E9 Vancouver (CAN)

info@silverviperminerals.com

+1-604-687-8566

Interview with Silver Viper: Future price drivers and takeover fantasy


10. December 2020 | 10:59 CET

AdTiger, Formycon, CureVac - Brilliant to the finish line!

  • Investments
Photo credits: pixabay.com

It seems strange that a single company should be worth as much as all its colleagues in the industry put together. There is no such thing - there is! Yesterday, Tesla had a valuation of USD 625 billion at the start of the stock market - that's more than all other car manufacturers put together. Of course, Elon Musk's creature has not been a pure car manufacturer for a long time. Tesla is a high-tech Company, led by a visionary who brings a new great idea from his inner design studio to the light of day every few weeks. With his visions about essential facts of the human future, he is as creative as Karl Lagerfeld and as crazy as Jean-Paul Gaultier. But everyone is looking for the favor of their customers and genius is what we urgently need in a pandemic environment.

time to read: 4 minutes by André Will-Laudien


 

Author

André Will-Laudien

Born in Munich, he first studied economics and graduated in business administration at the Ludwig-Maximilians-University in 1995. As he was involved with the stock market at a very early stage, he now has more than 30 years of experience in the capital markets.

About the author


AdTiger - Ingenious Marketing

AdTiger is an online advertising platform from China. Not well known in Europe so far, the agency deals with advertising contents of advertisers, as well as the diverse interests of the associated publishers. It is about efficient advertising channels, design and content. While Covid-19 spreads more and more across the planet, AdTiger managed to adjust its business model to the additional demand of app developers and educational institutions. The initially expected dent in growth quickly turned into public relevant projects and government contracts in the service of education and information of society.

Important in this context is good cooperation and the strong presence of AdTiger with social platforms such as Snapchat, Facebook, Twitter or Yahoo. Their growth also brings with it corresponding demand and potential in online business for AdTiger. Since the outbreak of the pandemic, online activities around the globe have grown by an average of 46%. In addition to contact platforms, the demand for online education and training is incomparably more vital than in previous years, at 27%.

All in all, AdTiger succeeds in transporting the lower circulation of offline media into a higher penetration of its online advertising content. Even if the pandemic should disappear one day, AdTiger has completely taken care of its digitization transfer and uses the changed habits of its clients to increase sales and profits. In pandemic times, ingenious marketing means contactless presence and content excellence. AdTiger currently costs EUR 78 million on the stock exchange and is listed in Frankfurt at EUR 0.13 per share. It is worth taking a closer look here.

Formycon - Genius Antibodies

We received another announcement in the area of Covid-19 control yesterday from Munich-based biosimilar expert Formycon. Since today, we know that Formycon is not only working on the biosimilars but also, with the help of Bavarian research funds, on the development of antibodies against the coronavirus. Based on Formycon's clinically validated experience with antibodies and antibody fusion proteins, the Company started the development of an ACE2 antibody fusion protein with the internal code FYB207 in March 2020 - shortly after the outbreak of the Covid-19 pandemic in Europe.

SARS-CoV-2 and other coronaviruses use ACE2 on the surface of human cells as an entry point for respiratory infections. Formycon has therefore linked the human ACE2 protein to the constant portion of human antibodies using computer-aided structural design, creating a very effective SARS-CoV-2 blocker. Different variants of the virus blocker were investigated on a laboratory scale for producibility, stability and virus inhibition. In vitro tests with isolates of SARS-CoV-2 as well as the original SARS-CoV from 2003 show that Formycon's ACE2 antibody fusion protein effectively binds to SARS coronaviruses and completely prevents infection of the cells. That sounds brilliant!

Compared to vaccines and therapeutic antibodies, the ACE2 antibody fusion protein is maximally protected against virus evasion by mutation. The risk of infection amplification by vaccines and IgG1 antibodies described for coronaviruses is minimized by using the IgG4 portion in the fusion. FYB207 also has inherent enzymatic activity that may provide additional protection for the lungs and cardiovascular system in symptomatic patients. Furthermore, FYB207 can potentially be used against all coronaviruses that use ACE2 as an entry point.

Formycon, together with its research partners, is receiving a grant of €290,000 from the Bavarian Research Foundation for this project. The share price went through the roof today with a plus of 75%, bringing the market capitalization to almost EUR 600 million in one go.

CureVac - Ingeniously placed

CureVac is a biopharmaceutical Company and has been owned for years by the Hopp family (known through the success story SAP). From the very beginning, the declared goal was to carry out research in precisely those areas which, for various reasons, the highly commercial pharmaceutical companies, in particular, leave out. It is an ironclad goal to take care of things that seem to promise little profit, but in the end, are a useful achievement. Again I am thinking of the cuckoo clock!

CureVac is a research Company in the field of mRNA technology, an essential part of human protein and immune research. With its expertise, CureVac is working on the development and optimization of the most versatile molecules for medical use. The principle of CureVac's proprietary technology is based on the use of mRNA as an information carrier to guide the body to produce appropriately encoded proteins that can be used to fight a variety of diseases. The Company applies its technologies to the development of prophylactic vaccines, cancer therapies, antibody therapies and protein therapies.

With approximately 500 employees today, CureVac has been researching difficult issues since 2000 and has not brought to light much of the essential research until early 2020. From 2006 to 2014, CureVac was financed solely by Dievini Hopp BioTech Holding, a biotech venture capital Company owned by Dietmar Hopp. Through this investment, CureVac's capital grew to a total of EUR 145 million. Then came COVID-19 and the Company, which had been burning money for two decades, was floated on the stock exchange at an initial valuation of USD 2.3 billion. The mission is now to produce a viable vaccine against Corona, and if you believe the stock market, the tenfold increase in the price from USD 14 to USD 140 probably carries the one important message: they can do it!

Regardless of how the story turns out, it was placed 100% ingeniously, because people like Dietmar Hopp are simply ingenious, even if it sometimes takes 20 years before the fruits can be harvested. With a current stock market valuation of EUR 24 billion without product, you will go down in history anyway.


Author

André Will-Laudien

Born in Munich, he first studied economics and graduated in business administration at the Ludwig-Maximilians-University in 1995. As he was involved with the stock market at a very early stage, he now has more than 30 years of experience in the capital markets.

About the author



Conflict of interest & risk note

In accordance with §34b WpHG we would like to point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH may hold long or short positions in the aforementioned companies and that there may therefore be a conflict of interest. Apaton Finance GmbH may have a paid contractual relationship with the company, which is reported on in the context of the Apaton Finance GmbH Internet offer as well as in the social media, on partner sites or in e-mail messages. Further details can be found in our Conflict of Interest & Risk Disclosure.


Related comments:

20. April 2021 | 09:45 CET | by Stefan Feulner

Varta, Sierra Growth, CureVac - Clear signals!

  • Investments

Sometimes, for various reasons, it takes longer before the positive developments of a Company are absorbed by the market and thus provide for price gains. It is currently similar to the precious metal gold, which is still in the consolidation phase. The facts such as national debt, inflation fears and the ultra-loose monetary policy of the central banks speak another clear language.

Read

20. April 2021 | 07:10 CET | by Carsten Mainitz

BioNTech, SunMirror, Steinhoff - Great News!

  • Investments

Shortly before the finish line, the going gets tough again. Many athletes and those who have to really "bite" in the last few meters before a deadline are probably familiar with this feeling. Everyday life in the Corona pandemic is also becoming more exhausting. Now, with BioNTech's announcement that it will double weekly vaccine dose deliveries to around 5.1 million units from the end of May, there may be a breakthrough in achieving herd immunity in Germany in the next few months. It is not only good news for the Company's shareholders but everyone. Below we present two other companies whose shareholders should be very pleased. Let us surprise you!

Read

15. April 2021 | 07:15 CET | by Stefan Feulner

Alibaba, The Place Holdings, CureVac - Great opportunities lie here!

  • Investments

The German vaccination disaster is going into the next round. After the AstraZeneca vaccine's back and forth and the question of whether only younger people, older people or no one should be vaccinated with the vaccine, the American vaccine manufacturer Johnson & Johnson is now experiencing delivery stoppages. The return to "normality" once again seems to be a long way off. Another question to ask yourself. What will future life in the new normal look like in the hard-pressed inner cities?

Read